Experimental Cancer Drug Navitoclax Demonstrates Potential to Enhance Tuberculosis Treatment Outcomes and Mitigate Permanent Lung Damage
Investigators from Johns Hopkins Medicine have reported that an experimental drug currently undergoing clinical trials...
